World's First WWOX Gene Therapy Given to Infant with WOREE Syndrome

Why It Matters

The administration of the first WWOX gene replacement therapy demonstrates that precision gene delivery to the central nervous system is feasible in a clinical setting, a milestone that could accelerate development pipelines for dozens of rare pediatric epilepsies. By moving a therapy from mouse models to a human infant, the case validates the translational model that many biotech firms rely on, potentially unlocking new funding streams and regulatory incentives for similar programs. Beyond the immediate patient, the success of this compassionate‑use intervention could reshape how rare‑disease sponsors design early‑stage studies, emphasizing rapid, targeted delivery methods and close collaboration with academic centers. If long‑term outcomes prove positive, the therapy may set a precedent for regulatory pathways that balance urgent unmet medical need with rigorous safety monitoring, influencing policy for gene‑based treatments worldwide.

Key Takeaways

• Eight‑month‑old infant received first‑in‑human WWOX gene therapy for WOREE syndrome at Schneider Children’s Medical Center, Israel.
• Therapy uses an AAV9 vector to deliver a functional copy of the WWOX gene directly into the brain via cisterna magna injection.
• Developed by Mahzi Therapeutics, licensed from Hebrew University’s Prof. Rami Aqeilan’s laboratory after a decade of pre‑clinical work.
• One month post‑treatment the child is clinically stable with no recurrence of severe seizures; long‑term safety and efficacy remain under observation.
• The case opens a pathway for gene‑replacement strategies targeting other monogenic neurodevelopmental disorders.

Pulse Analysis

The breakthrough underscores a shift in biotech strategy from systemic gene delivery to targeted central‑nervous‑system approaches. Historically, AAV‑based therapies have focused on liver or muscle targets; delivering a vector across the blood‑brain barrier has been a major hurdle. The cisterna magna injection used here bypasses that barrier, offering a scalable method for other brain‑focused indications. This technical advance could lower development costs and accelerate timelines for rare neurological diseases, where patient populations are too small to support traditional large‑scale trials.

From a market perspective, Mahzi Therapeutics now sits at the nexus of academic discovery and commercial translation. While the company has not disclosed financing, the visibility of this first‑in‑human case is likely to attract Series B or C funding, especially from investors betting on the next wave of gene‑editing and gene‑replacement platforms. Competitors such as Spark Therapeutics and Regenxbio have already pursued AAV9 vectors for spinal muscular atrophy and other CNS disorders; Mahzi’s focus on loss‑of‑function neurodevelopmental genes could carve out a distinct niche.

Looking ahead, the key risk remains the durability of expression and immune tolerance to the AAV capsid. Early data are promising, but the field has seen setbacks when neutralizing antibodies limit repeat dosing. If Mahzi can demonstrate sustained WWOX expression without adverse immune reactions, it will set a benchmark for regulatory agencies evaluating similar therapies. The upcoming Phase 1/2 trial will be closely watched, not only by families affected by WOREE syndrome but also by the broader rare‑disease community, which sees this as a potential template for turning decades‑old genetic discoveries into life‑saving treatments.